Not just AstraZeneca — CanSino Biologics also unveils Phase II data, showing antibody and T cell response
The biotech and infectious disease world — much of the world, really — sat eagerly anticipating the early Covid-19 vaccine data AstraZeneca and the Lancet had promised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.